Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 18/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 15/20 | 1.00 |
| ▸ | GAA | P10253 | 13/20 | 1.00 |
| ▸ | MAPT | P10636 | 11/20 | 1.00 |
| ▸ | GLA | P06280 | 10/20 | 1.00 |
| ▸ | HTT | P42858 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | SAE1 | Q9UBE0 | 4/20 | 0.85 |
| ▸ | UBA2 | Q9UBT2 | 4/20 | 0.85 |
| ▸ | HPGD | P15428 | 12/20 | 0.82 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.76 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.70 |
| ▸ | CASP1 | P29466 | 4/20 | 0.70 |
| ▸ | CASP7 | P55210 | 4/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.70 |
| ▸ | PKM | P14618 | 3/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | USP2 | O75604 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17817473 | 0.96 | KDM4E (0.92) | KDM4EALDH1A1GAAMAPTGLA | |
| SCHEMBL17817474 | 0.96 | KDM4E (0.92) | KDM4EALDH1A1GAAMAPTGLA | |
| SCHEMBL6981236 | 0.93 | KDM4E (0.88) | KDM4EALDH1A1GAAMAPTGLA | |
| SCHEMBL15256914 | 0.92 | SAE1 (1.00) | KDM4EALDH1A1GAAMAPTGLA | |
| SCHEMBL15256861 | 0.82 | SAE1 (0.77) | KDM4EALDH1A1GAAMAPTGLA | |
| SCHEMBL15256901 | 0.82 | KDM4E (1.00) | KDM4EALDH1A1GAAMAPTGLA | |
| SCHEMBL15256869 | 0.81 | KDM4E (0.75) | KDM4EALDH1A1GAAMAPTGLA | |
| SCHEMBL15256919 | 0.81 | KDM4E (0.68) | KDM4EALDH1A1GAAMAPTGLA | |
| SCHEMBL6981812 | 0.80 | SAE1 (0.89) | KDM4EALDH1A1GAAMAPTGLA | |
| SCHEMBL15256916 | 0.76 | KDM4E (0.62) | KDM4EALDH1A1GAAMAPTGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045483-B2 | Inhibition of small ubiquitin-like modifier enzymes with substituted pyrrolo[2,3-b]quinoxalines | CITY OF HOPE (US) | 2015-06-02 | — | — | US | disclosed |
| US-9045483-B2 | Inhibition of small ubiquitin-like modifier enzymes with substituted pyrrolo[2,3-b]quinoxalines | CITY OF HOPE (US) | 2015-06-02 | — | — | US | disclosed |
| US-20130245032-A1 | BICYCLIC AND TRICYCLIC INHIBITORS OF SUMOYLATION ENZYMES AND METHODS OF THEIR USE | Sanford-Burnham Medical Research Institute at Lake Nona (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130245032-A1 | BICYCLIC AND TRICYCLIC INHIBITORS OF SUMOYLATION ENZYMES AND METHODS OF THEIR USE | Sanford-Burnham Medical Research Institute at Lake Nona (US) | 2013-09-19 | — | — | US | disclosed |
| WO-2012064897-A2 | BICYCLIC AND TRICYCLIC INHIBITORS OF SUMOYLATION ENZYMES AND METHODS FOR THEIR USE | CHEN YUAN (US) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245032-A1 | BICYCLIC AND TRICYCLIC INHIBITORS OF SUMOYLATION ENZYMES AND METHODS OF THEIR USE | SUMO1, SUMO2, SAE1 | KDM4E 386/4885ALDH1A1 1193/4885GAA 1531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.